Your Location is set to:

PROMINENT

Objective

The objective of the study is to find out if K-877 (also called pemafibrate), the study drug, compared to placebo (treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular complications in adults with type-2 diabetes.  Those complications may be a heart attack or a stroke.

Principal Investigator(s)
Richard Zelman, MD

Clinical Trial Categories

  • Cardiovascular Disease with Diabetes
  • Cardiovascular Disease
  • Coronary Disease
Contact
Kelcie Brown, RN at
or kelciebrown@capecodhealth.org
How to Participate

Speak to your primary care physician/cardiologist or to our experienced research nurse:  Kelcie Brown, RN at 508-778-5900.

Location

  • Heart & Vascular Institute